The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
Recruiting now
Conditions studied: Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome, Trisomy 13, Trisomy 18, Sex Chromosome Abnormalities
In brief
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Key facts
- Study ID
- NCT07643896
- Run by
- BillionToOne Inc.
- People needed
- 1000
- Starts
- 2026-01-10
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-06-12
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- pregnant individuals between 10 and 20 weeks of gestation
- singleton gestation
You may not qualify if…
- active cancer
Where it is running
- Valley Perinatal Services — Phoenix, Arizona, United States (enrolling)
- San Gabriel Valley Perinatal Medical Group — West Covina, California, United States (enrolling)
- Sarasota Memorial Health Care System — Sarasota, Florida, United States (enrolling)
- Pediatrix Medical Group of Georgia — Atlanta, Georgia, United States (enrolling)
- Woman's Hospital — Baton Rouge, Louisiana, United States (enrolling)
- Pediatrix Medical Group — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.